Fig. 1: Proportions of HAWK and HARRIER patients with early persistent fluid (IRF and/or SRF), early persistent SRF (with or without IRF) and early persistent IRF (with or without SRF) at baseline and at Weeks 4, 8 and 12. | Eye

Fig. 1: Proportions of HAWK and HARRIER patients with early persistent fluid (IRF and/or SRF), early persistent SRF (with or without IRF) and early persistent IRF (with or without SRF) at baseline and at Weeks 4, 8 and 12.

From: Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies

Fig. 1

Note that the ‘early persistent SRF’ group comprises subjects with the presence of SRF at all study visits through Week 12 and likewise for the ‘early persistent IRF’ group whereas the ‘early persistent fluid’ group includes subjects with either fluid at these visits. IRF intraretinal fluid, SRF subretinal fluid.

Back to article page